UroGen Pharma Ltd.
NASDAQ:URGNBiotechnology
-$0.40 today
- Market cap
- $1.46B
- Beta
- 1.62
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$2.65
Volume 1.14M
Average 0.79M
URGN Total Current Liabilities
All obligations due within one year.
UroGen Pharma Ltd.NASDAQ: URGN
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 20.6% from a year ago
Total current liabilities stood at $50.64M at the end of Q1 FY2026, up 20.6% from a year earlier and up 9.1% from the prior quarter. Over 3 fiscal years it compounded at +24.7% a year.
Context
- Total current liabilities amounted to 20.0% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +20.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 46.42M USD
- Year-over-year change
- +1.0%
- 4-year CAGR
- +20.0%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.42M | +1.0% |
| FY2024 | 2024-12-31 | 45.95M | +47.2% |
| FY2023 | 2023-12-31 | 31.21M | +30.5% |
| FY2022 | 2022-12-31 | 23.92M | +6.9% |
| FY2021 | 2021-12-31 | 22.38M | — |
Total Current Liabilities vs competitors
How URGN compares with its peers on the latest reported figures
- URGN's Mar 2026 total current liabilities of $50.64M is the highest of the 3 companies compared; the peer median is $29.66M.
- Its year-over-year change of +20.6% is the lowest of 3, against a peer median of +99.3%.
- Total current liabilities amounts to 20.0% of total assets for URGN, versus a peer median of 5.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $50.64M | +20.6% | +24.7% | 20.0% | |
| Sep 2026 | $46.43M | +52.1% | +26.0% | 4.4% | |
| Mar 2026 | $12.89M | +146.4% | -19.8% | 5.5% | |
| Peer median (excluding URGN) | $29.66M | +99.3% | +3.1% | 5.0% | |
Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 44.36M | 55.41M | 95M | 171.99M | 110.75M |
| Short-term Investments | 44.78M | 44.56M | 41.97M | 64.7M | 9.71M |
| Net Receivables | 11.72M | 12.7M | 15.44M | 20.3M | 33.08M |
| Inventory | 4.83M | 4.33M | 5.67M | 9.23M | 16.46M |
| Other Current Assets | 1.23M | 11.91M | 11.1M | 9.92M | 16.02M |
| Total Current Assets | 114.39M | 128.91M | 169.19M | 276.14M | 186.02M |
| Property, Plant & Equipment (Net) | 3.15M | 3.75M | 2.36M | 3.79M | 9.09M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 675K | 0 | 4.5M | 5.02M | 177K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.53M | 2.96M | 2.26M | 765K | 5.16M |
| Total Non-current Assets | 5.36M | 6.71M | 9.13M | 9.58M | 14.43M |
| Total Assets | 119.75M | 135.62M | 178.31M | 285.71M | 200.46M |
| Account Payables | 5.79M | 5.53M | 6.51M | 10.93M | 12.14M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.28M | 11.53M | 14.67M | 18.52M | 18.7M |
| Total Current Liabilities | 22.38M | 23.92M | 31.21M | 45.95M | 46.42M |
| Long-term Debt | 0 | 97.54M | 98.55M | 121.73M | 122.21M |
| Deferred Tax Liabilities | 2.84M | 3.02M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 85.71M | 98.92M | 112.92M | 125.18M | 131.18M |
| Total Non-current Liabilities | 88.95M | 201.06M | 212.31M | 248.57M | 259.51M |
| Total Liabilities | 111.33M | 224.98M | 243.52M | 294.51M | 305.93M |
| Common Stock | 61K | 63K | 89K | 115K | 133K |
| Retained Earnings | (467.32M) | (577.1M) | (679.35M) | (806.22M) | (959.72M) |
| Accumulated OCI | (25K) | (107K) | 12K | 56K | 19K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 8.41M | (89.36M) | (65.21M) | (8.8M) | (105.47M) |
| Total Debt | 398K | 99.12M | 99.4M | 123.39M | 128.33M |
| Net Debt | (43.96M) | 43.72M | 4.39M | (48.6M) | 17.59M |
UroGen Pharma Ltd.
NASDAQ:URGN
Intrinsic Alpha fair value
Locked
Current Price
$29.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.